A large-scale study has revealed the impact of germline variants on proteins in 10 cancer types. Scientists from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted a precision proteogenomic analysis in a pan-cancer study with data from 1,064 patients, identifying tumor heterogeneity and tumorigenesis associated with heritable genetic alterations. The results provide a broad view of cancer risk that could be useful for patient stratification and the design of prevention strategies.

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), researchers from Rutgers University investigated the therapeutic potential of CJRB-302, a live biotherapeutic product derived from healthy human gut microbiota, to improve PD motor symptoms and pathology.

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), researchers from Beijing Joekai Biotechnology LLC presented the discovery process and preclinical results for 50561.

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), Promis Neurosciences Inc. presented its new approach to optimizing the α-synuclein (α-Syn) vaccine composition in order to maximize targeting of toxic α-Syn species.

Researchers from Violet Therapeutics Inc. presented the discovery of VTT-001, a novel EPHB3 inhibitor designed to target astrocyte-mediated disease mechanisms.

BHV-8000 from Biohaven Pharmaceuticals Inc. is a dual, brain-penetrant, oral small molecule that is highly selective against TYK2 and JAK1 enzymes, which are essential enzymes to the inflammatory response driving the progression of many neuroinflammatory and neurodegenerative diseases, such as Parkinson’s disease (PD).